Filing Flows › Vertex Pharmaceuticals (VRTX) › Guidance history
Vertex Pharmaceuticals (VRTX) guidance history: what it guided and what it reported
Vertex Pharmaceuticals gave guidance in 9 earnings releases on file since Nov 6, 2023. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +0.4% against the guided midpoint. Its releases raised guidance 4 times and lowered it once.
Revenue
Met or beat 1 of 1 periods (0 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $12.0B (Feb 12, 2026) → raised $12.9B–$13.1B (May 4, 2026) → raised $13.1B–$13.2B (Aug 3, 2026) → raised $13.2B–$13.2B (Nov 2, 2026) | — | to be reported | — |
| FY2025 | $11.8B–$12.0B (Feb 10, 2025) → raised $11.8B–$12.0B (May 5, 2025) → raised $11.9B–$12.0B (Nov 3, 2025) | $12.0B | within the range | +0.4% |
Adjusted operating expenses
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $5.7B–$5.8B (Nov 3, 2025) | — | — | — |
Adjusted tax rate
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 20.5%–21.5% (Aug 4, 2025) → reaffirmed 20.5%–21.5% (Nov 3, 2025) | — | — | — |
The latest quarter
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
Does Vertex Pharmaceuticals beat its guidance?
Vertex Pharmaceuticals gave guidance in 9 earnings releases on file since Nov 6, 2023. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +0.4% against the guided midpoint.
How often does Vertex Pharmaceuticals raise guidance?
Its earnings releases raised guidance 4 times and lowered it once since Nov 6, 2023.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.